A new pancreatic cancer pill called daraxonrasib showed significant tumour reduction in a clinical trial. Nearly all patients saw growth stop, with some achieving undetectable cancer levels.
A daily pancreatic cancer pill has shown remarkable results in early trials, with tumours becoming undetectable in some patients. Experts call it a major breakthrough.